Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2023)

Historic Total Current Liabilities for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $10.3 million.

  • Candel Therapeutics' Total Current Liabilities rose 7509.33% to $10.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $10.3 million, marking a year-over-year increase of 7509.33%. This contributed to the annual value of $5.6 million for FY2022, which is 471.84% up from last year.
  • Latest data reveals that Candel Therapeutics reported Total Current Liabilities of $10.3 million as of Q3 2023, which was up 7509.33% from $8.2 million recorded in Q2 2023.
  • Candel Therapeutics' 5-year Total Current Liabilities high stood at $10.3 million for Q3 2023, and its period low was $4.4 million during Q3 2021.
  • Its 4-year average for Total Current Liabilities is $6.0 million, with a median of $5.5 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Candel Therapeutics' Total Current Liabilities was 7509.33% (2023), while the steepest drop was 431.29% (2023).
  • Quarter analysis of 4 years shows Candel Therapeutics' Total Current Liabilities stood at $4.7 million in 2020, then increased by 13.77% to $5.4 million in 2021, then grew by 4.72% to $5.6 million in 2022, then soared by 83.92% to $10.3 million in 2023.
  • Its Total Current Liabilities was $10.3 million in Q3 2023, compared to $8.2 million in Q2 2023 and $5.2 million in Q1 2023.